Quince Therapeutics, Inc. Subsidiaries
Every subsidiary the company listed in Exhibit 21 of its annual reports, newest list first (2 lists). Names and jurisdictions are as filed.
- 2025-03-24: Subsidiary Cortexyme Australia Pty Ltd; Jurisdiction Australia.
- 2025-03-24: Subsidiary Novosteo, LLC; Jurisdiction Delaware.
- 2025-03-24: Subsidiary Novosteo Pty Ltd; Jurisdiction Australia.
- 2025-03-24: Subsidiary EryDel US, Inc.; Jurisdiction Delaware.
| Annual report filed | Subsidiary | Jurisdiction |
|---|---|---|
| 2025-03-24 | Cortexyme Australia Pty Ltd | Australia |
| 2025-03-24 | Novosteo, LLC | Delaware |
| 2025-03-24 | Novosteo Pty Ltd | Australia |
| 2025-03-24 | EryDel US, Inc. | Delaware |
| 2025-03-24 | EryDel USA, Inc. | New Jersey |
| 2025-03-24 | EryDel Italy, Inc. | Delaware |
| 2025-03-24 | Quince Therapeutics, S.p.A | Italy |
| 2024-04-01 | Entity Name | Jurisdiction of Incorporation |
| 2024-04-01 | Cortexyme Australia Pty Ltd | Australia |
| 2024-04-01 | Novosteo, LLC | Delaware |
| 2024-04-01 | Novosteo Pty Ltd | Australia |
| 2024-04-01 | EryDel US, Inc. | Delaware |
| 2024-04-01 | EryDel USA, Inc. | New Jersey |
| 2024-04-01 | EryDel S.p.A | Italy |
| 2024-04-01 | EryDel Italy, Inc. | Delaware |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |